<DOC>
	<DOCNO>NCT00140387</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy prim vaccination , subsequent boosting vaccination Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines ( Allogeneic Prostate GVAX® ) . Clinical observation laboratory measurement monitor evaluate safety toxicity . Additionally , antitumor effect Allogeneic Prostate GVAX® serum PSA level evaluate antitumor response quantitated .</brief_summary>
	<brief_title>Prime-Boost Dose Scheduling Trial Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines ( Allogeneic Prostate GVAX® )</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Diagnosis adenocarcinoma prostate cancer No evidence measurable metastatic disease An ECOG performance status 0 1 Previous hormonal therapy type prostate cancer Any previous chemotherapy , prior investigational therapy prostate cancer Prior Immunotherapy Prior treatment gene therapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>Prostate</keyword>
	<keyword>Cancer</keyword>
	<keyword>GVAX</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Allogeneic cell</keyword>
</DOC>